Thymosin Alpha-1
Immune-modulating peptide with global approval and ongoing US trials.
- Primary research area
- Immune / antiviral
- FDA status
- Approved in 30+ countries; US investigational
- Last updated
- Apr 21, 2026
- Reviewed by
- Peptide Examiner editorial team
What it is
Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide derived from prothymosin alpha, a protein secreted by the thymus. It is one of the most widely-researched immune-modulating peptides and is approved as a drug in more than 30 countries under the brand name Zadaxin. In the United States it is investigational — Phase 3 trials have been conducted but no FDA approval has been granted.
Mechanism of action
Thymosin alpha-1 modulates the immune system broadly, with effects including maturation of T lymphocytes (particularly CD4 helper cells), enhancement of dendritic cell function, increased cytokine production (IL-2, IFN-γ), and modulation of regulatory T cells. The net effect is immunostimulant in contexts of immune suppression (cancer, chronic viral infection, sepsis) and potentially immunomodulatory in autoimmune contexts.
Research history
Decades of clinical research across global approvals. Approved indications internationally include adjuvant therapy in chronic hepatitis B and C, cancer chemotherapy support, and immune enhancement in severe sepsis. US development has progressed through Phase 3 for several indications, but broader FDA approval has not followed. A large 2013 Phase 3 trial in severe sepsis reported a mortality benefit; FDA review has not resulted in US approval.
Current trial status
Approved in 30+ countries. US: investigational, with Phase 3 exposure for multiple indications. No active FDA approval pending as of April 2026.
Regulatory status
Not FDA approved. Not on Category 2 list as of the 2023 listing (note: verify current status on FDA tracker). Available via compounding in the US in some contexts. Full regulatory timeline →
Controversies and open questions
The US-vs-rest-of-world regulatory divergence is unusual and raises questions about what's different in FDA review. Thymosin alpha-1 has better human evidence than most peptides marketed for research use, yet remains unapproved in the US. Commercial considerations, indication specificity, and regulatory pathway choice likely all play a role.
Further reading
Frequently asked
Is thymosin alpha-1 approved anywhere?
Yes — approved in 30+ countries as Zadaxin for indications including chronic hepatitis B/C adjuvant therapy, cancer chemotherapy support, and severe sepsis. Not FDA approved in the US despite Phase 3 trial exposure.
Why isn't it FDA approved in the US?
Phase 3 trials have been conducted, but broader FDA approval has not followed. Reasons likely include pathway choice, commercial priorities, and indication specificity. The US is genuinely an outlier relative to the global regulatory landscape.
Can I get it via compounding?
Limited availability. Not explicitly on the 2023 Category 2 list like other peptides, but regulatory status in the US is investigational. Consult an FDA-compliant compounding pharmacy to verify current status.
What's the strongest evidence?
A 2013 Phase 3 trial in severe sepsis reported a mortality benefit — rare in sepsis research. The evidence is more credible than for most peptides in biohacker circulation.